J&J: Brussels approves Dazalex for multiple myeloma

(CercleFinance.com) - Janssen, a Johnson & Johnson subsidiary, announced on Tuesday that it has received the European Commission's marketing authorisation for Darzalex for the treatment of multiple myeloma.


Brussels' approval concerns the use of Darzalex in combination with bortezomib, thalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.

Darzalex, a new kind of biological product, targets a gene that is strongly expressed in multiple myeloma cells, regardless of the stage of the disease.

The drug induces the death of tumour cells by numerous
mechanisms of action for the treatment of immune-mediated diseases.


Copyright (c) 2020 CercleFinance.com. All rights reserved.